类风湿关节炎的发病机制及药物治疗研究进展  

Research progress on the pathogenesis and drug treatment of rheumatoid arthritis

作　　者：苏雨荷 王刚 文振华[1] 田锋[1] 李敬扬[1] SU Yuhe;WANG Gang;WEN Zhenhua;TIAN Feng;LI Jingyang(Zhuzhou Hospital Affiliated to Xiangya School of Medicine,Central South University,Zhuzhou 412000,China)

机构地区：[1]中南大学湘雅医学院附属株洲医院,株洲412000

出　　处：《西北药学杂志》2021年第5期857-862,共6页Northwest Pharmaceutical Journal

基　　金：湖南省自然科学基金青年基金项目(编号:2017JJ4069)。

摘　　要：目的了解类风湿关节炎(RA)的发病机制及药物治疗研究进展。方法查阅并总结相关文献,对国内外RA的发病机制及药物治疗研究进展进行综述。结果RA的发病机制包括炎性细胞因子、炎性介质和自身抗体的介导及细胞内信号传递。RA的治疗药物有糖皮质激素(GCs)、非甾体抗炎药(NSAIDS)、传统合成的改善病情的抗风湿药物(csDMARDs)、生物类改善病情的抗风湿药物(bDMARDs)和靶向合成类改善病情的抗风湿药物(tsDMARDs)等。结论近年来,将csDMARDs与bDMARDs或tsDMARDs联用取得了更好的临床效果,可改善患者的生活质量,减缓患者关节损伤的放射学进展,成为新的研究热点。Objective To understand the pathogenesis of rheumatoid arthritis(RA)and the progress of drug therapy.Methods The literatures about the mechanism of RA and the clinical progress of drugs were reviewed and summarized.Results The pathogenesis of RA includes inflammatory cytokines,inflammatory mediators,autoantibodies mediated and intracellular signaling.The therapeutic agents for RA include glucocorticoids(GCs),nonsteroidal anti-inflammatory drugs(NSAIDS),conventional synthetic disease-modifying anti-rheumatic drugs(csDMARDs),biologic disease-modifying antirheumatic drugs(bDMARDs),targeted synthetic disease-modifying anti-rheumatic drugs(tsDMARDs),etc..Conclusion In recent years,the combination of csDMARDs and bDMARDs or tsDMARDs has become a hot research topic to improve the quality of life of patients and slow down the radiological progress of joint injury.

关 键 词：类风湿关节炎(RA) 糖皮质激素(GCS) 非甾体抗炎药(NSAIDS) 抗风湿药物 

分 类 号：R982[医药卫生—药品]